

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JUNE 9, 2020;**

**(2) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND
(3) CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE**

The Board announces that:

- (1) At the AGM held on June 9, 2020, save for resolution numbered 8, all proposed resolutions as set out in the notice of the AGM dated May 11, 2020 were duly passed by the relevant shareholders of the Company by way of poll;
- (2) Mr. Wo Felix Fong retired as an independent non-executive Director with effect from the conclusion of the AGM and therefore he ceased to be a member of the Remuneration Committee; and
- (3) Mr. Kenneth Walton Hitchner III has been appointed as an independent non-executive Director with effect from the conclusion of the AGM and was appointed a member of the Remuneration Committee on the same date.

POLL RESULTS OF THE AGM HELD ON JUNE 9, 2020

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on June 9, 2020, save for resolution numbered 8, all proposed resolutions as set out in the notice of the AGM dated May 11, 2020 were duly passed by the relevant shareholders of the Company by way of poll. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the circular dated May 11, 2020 (the “**Circular**”).

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and of the independent auditor of the Company for the year ended December 31, 2019.	1,015,489,844 (99.98%)	166,620 (0.02%)
2.	(a) To re-elect Dr. Ge Li as non-executive Director.	898,931,650 (88.45%)	117,336,314 (11.55%)
	(b) To re-elect Dr. Zhisheng Chen as executive Director.	987,675,218 (97.19%)	28,592,746 (2.81%)
3.	To elect Mr. Kenneth Walton Hitchner III as independent non-executive Director.	1,014,383,572 (99.81%)	1,884,392 (0.19%)
4.	To authorise the Board or any duly authorised board committee to fix the Directors' remuneration for the year ending December 31, 2020.	1,004,154,504 (98.89%)	11,263,960 (1.11%)
5.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorise the Board or any duly authorised board committee to fix their remuneration.	1,012,064,273 (99.67%)	3,378,191 (0.33%)
6.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company.	510,088,776 (50.23%)	505,329,688 (49.77%)
7.	To grant a general mandate to the Directors to repurchase the shares of the Company.	1,013,325,264 (99.79%)	2,149,200 (0.21%)
8.	To extend the general mandate granted to the Directors to issue, allot and deal with the shares of the Company by adding thereto the shares to be repurchased by the Company.	495,444,656 (48.75%)	520,823,308 (51.25%)
9.	(a) To grant a specific mandate to the Directors to issue and allot the Connected Restricted Shares; and	747,143,787 (73.52%)	269,124,177 (26.48%)
	(b) To authorise any one of the Directors to take any action for and on behalf of the Company to carry out the issue and allotment of the Connected Restricted Shares under the specific mandate and the transactions contemplated thereunder.	747,970,130 (73.60%)	268,297,834 (26.40%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
10.	To grant 392,932 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Dr. Zhisheng Chen.	747,143,787 (73.52%)	269,124,177 (26.48%)
11.	To grant 117,879 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Dr. Weichang Zhou.	740,774,287 (72.89%)	275,493,677 (27.11%)
12.	To grant 4,560 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Edward Hu.	739,517,787 (72.77%)	276,750,177 (27.23%)
13.	To grant 2,280 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. William Robert Keller.	739,517,787 (72.77%)	276,750,177 (27.23%)
14.	To grant 4,560 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Teh-Ming Walter Kwauk.	739,517,787 (72.77%)	276,750,177 (27.23%)

As at the date of the AGM, the total number of shares of the Company in issue was 1,309,116,412 Shares.

As stated in the Circular, the respective Connected Grantees and their respective associates holding Shares were required to abstain and they had abstained from voting on the relevant resolutions numbered 9 to 14 in respect of the grant of Specific Mandate and the grant of Connected Restricted Shares to Connected Grantees proposed at the AGM.

To the best knowledge and belief of the Company, after making all reasonable enquiries, as at the date of the AGM, (i) Dr. Zhisheng Chen and his associates hold 1,211,418 Shares; (ii) Mr. Edward Hu and his associates hold 712,500 Shares; (iii) Mr. William Robert Keller and his associates hold 2,824 Shares; and (iv) Dr. Weichang Zhou and Mr. Teh-Ming Walter Kwauk and their respective associates do not hold any Shares.

Accordingly, as at the date of the AGM, the respective total number of Shares entitling the holders to attend and vote on resolutions numbered 1 to 8 were 1,309,116,412 Shares, being the total number of issued Shares as at the date of the AGM, and on resolutions numbered 9 to 14 were 1,307,189,670 Shares, 1,307,904,994 Shares, 1,309,116,412 Shares, 1,308,403,912 Shares, 1,309,113,588 Shares and 1,309,116,412 Shares, respectively.

Save as disclosed above, there were no restrictions on any shareholders of the Company to cast votes on any of the resolutions proposed at the AGM. No shareholder of the Company has stated his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company's Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr. Fong did not offer himself for re-election of Director at the AGM as he wishes to devote more time to his other personal and business commitments. Therefore, Mr. Fong retired from office as an independent non-executive Director upon conclusion of the AGM.

Mr. Fong has confirmed that there is no disagreement between him and the Board, and there are no matters relating to his retirement that need to be brought to the attention of the Shareholders or the Stock Exchange.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is also pleased to announce that Mr. Hitchner has been appointed as an independent non-executive Director with effect from the conclusion of the AGM. The biographical details of Mr. Hitcher are as follows:

Mr. Kenneth Walton Hitchner III, aged 60, has more than 30 years of experience in corporate finance. He served as the Chairman and Chief Executive Officer of The Goldman Sachs Group, Inc. in Asia Pacific Ex-Japan before his retirement in 2019. He was also a member of Goldman Sachs' Management Committee and co-chaired its Asia Pacific Management Committee.

Previously, Mr. Hitchner served as President of Goldman Sachs in Asia Pacific Ex-Japan from 2013 to 2017. Prior to relocating to Hong Kong, he was global head of Goldman Sachs' Healthcare Banking Group and global co-head of its Technology, Media and Telecom Group. He was named managing director in 2000 and partner in 2002. He became head of the global medical device banking practice in 1998 and head of the global pharmaceutical banking practice in 2001. He began his career with Goldman Sachs' Corporate Finance Department in 1992.

Mr. Hitchner obtained a bachelor's degree in arts from the University of Colorado in 1982 and a master's degree in business administration (MBA) as a merit fellow from Columbia University Business School in 1992.

Save as disclosed above, Mr. Hitchner does not, at present, nor did he in the past three years, hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas.

Mr. Hitchner has entered into a service contract with the Company for a term of three years which is terminable by either party with three months' written notice, and he is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the provision of the Articles of Association. Mr. Hitchner does not have any relationships with any Directors or senior management or substantial shareholders or controlling shareholders of the Company.

As at the Latest Practicable Date, Mr. Hitchner did not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the SFO. Mr. Hitchner is entitled to a director's remuneration of HK\$450,000 per annum as determined by the Board with reference to his duties and responsibilities, the prevailing market conditions and the recommendation from the Remuneration Committee. The remuneration may be paid in the form of cash or restricted shares, or a combination of both (less any necessary statutory deductions), as agreed by the parties from time to time.

There is no information which is discloseable nor is/was Mr. Hitchner involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the Mr. Hitchner's election that need to be brought to the attention of the Shareholders and the Stock Exchange.

CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE

Subsequent to Mr. Fong's retirement as an independent non-executive Director, he ceased to be a member of the Remuneration Committee with effect from June 9, 2020. The Board further announces that Mr. Hitchner was appointed as a member of the Remuneration Committee with effect from June 9, 2020.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Fong for his valuable contributions to the Group during his tenure of office, and would like to extend its warmest welcome to Mr. Hitchner on his new appointment.

For and on behalf of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, June 9, 2020

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*